Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Balıkesir Medical JournalOpen Access

Risk Factors Affecting Spontaneous Pleurodesis After Indwelling Tunneled Catheter Application in Malignant Pleural Effusion

View Full Paper
Ask AI
Bookmark
Share

Authors

HEHıdır Eşme

Discussion

Loading...

Member takes

Overview

This observational analysis identifies risk factors affecting spontaneous pleurodesis in patients using indwelling tunneled catheters, suggesting key considerations for treatment.

Key Points

  • Spontaneous pleurodesis occurred in relation to the time interval before the indwelling tunneled catheter application.
  • Patients with an entrapped lung showed a significant correlation with increased success rates of spontaneous pleurodesis.
  • Observational analysis included 34 patients from a thoracic surgery clinic, gathering extensive demographic and clinical data.
  • Findings highlight significant risk factors in achieving spontaneous pleurodesis, emphasizing the importance of timely intervention.

Cite This Study

Hıdır Eşme (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d64781a2ahttps://doi.org/10.33716/bmedj.1621439
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Multicenter Analysis of Factors Predicting Treatment Success for Intrapleural Enzyme Therapy for Pleural Infection2025
  2. 2Assessment of Tetracycline Pleurodesis in Primary Spontaneous Pneumothorax2025
  3. 3Synergistic Sealing of the Pleural Space: Combining Thoracoscopic Talc Poudrage and <scp>IPC</scp> for Malignant Pleural Effusion—A Case Series2025
  4. 4Short-term outcomes of nonintubated and intubated video-assisted thoracoscopic surgery in management of malignant pleural effusion2025 · 2 citations
  5. 5Prognostic factors and treatment outcomes in EGFR-mutated NSCLC with malignant pleural effusion: focus on intrathoracic chemotherapy and EGFR-TKI therapy2025